Research & Development / Alliance Management
Progress Proprietary Pipeline
MOR103
The phase 1 clinical trial for MOR103 in healthy volunteers has been completed and is currently in the analysis stage. The final data will be reported in Q2 2009. Additional preclinical investigations of MOR103 in animal models for other inflammatory diseases are currently being conducted.
MOR202
The preclinical development and manufacturing of MOR202 continues as planned. Start of clinical development is expected in 2010.
MOR203/MOR205
MorphoSys has selected two new disease-related target molecules in oncology, which build the basis for the therapeutic antibody programs MOR203 and MOR205. The program MOR203 was started during the first quarter of 2009, MOR205 will be started in the second quarter of 2009.
Progress Partnered Pipeline
During the first quarter of 2009, MorphoSys’s existing partnered therapeutic antibody pipeline increased to 57 active antibody compounds in total (up from 55 at the beginning of the year), of which currently four compounds are in clinical development, 30 in preclinical development, and 23 in research (not including the potential co-development with Novartis).
During the first quarter, Novartis has advanced the HuCAL-based antibody program BHQ880 into a phase 1/2 combination study.